Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Q3 2025 value amounting to $366000.0.

  • Lineage Cell Therapeutics' Interest & Investment Income fell 780.86% to $366000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 202.78%. This contributed to the annual value of $1.7 million for FY2024, which is 527.93% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Interest & Investment Income is $366000.0, which was down 780.86% from $454000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Interest & Investment Income registered a high of $478000.0 during Q1 2025, and its lowest value of $2000.0 during Q1 2021.
  • Moreover, its 4-year median value for Interest & Investment Income was $407000.0 (2023), whereas its average is $387000.0.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Interest & Investment Income tumbled by 9950.62% in 2021 and then surged by 2120.42% in 2024.
  • Over the past 4 years, Lineage Cell Therapeutics' Interest & Investment Income (Quarter) stood at $2000.0 in 2021, then soared by 20100.0% to $404000.0 in 2023, then dropped by 2.72% to $393000.0 in 2024, then fell by 6.87% to $366000.0 in 2025.
  • Its last three reported values are $366000.0 in Q3 2025, $454000.0 for Q2 2025, and $478000.0 during Q1 2025.